COMPASS Pathways plc

COMPASS Pathways is developing COMP360, a synthetic psilocybin formulation for treatment-resistant depression — the leading pure-play in the psychedelic-drug approval race. The stock is up 274% over the past year on positive Phase 3 data readouts.

• Revenue is zero last quarter — this is a clinical-stage biotech; the equity value is entirely on COMP360 approval probabilities and the eventual TRD commercial launch trajectory.
• The July 7 26-week COMP006 Phase 3 results announcement is the specific catalyst driving the tape — positive durability data plus continued efficacy signal validate the mechanism.
• Evercore upgraded to Outperform with PT $21 (up from $8) expecting potential FDA approval — real sell-side conviction backing the community's psychedelic-approval thesis.
• Cathie Wood's ARKG accumulating shares is a real institutional signal — ARKG's biotech-picking mixed track record adds nuance but the flow is meaningful for a name at 82nd percentile of 52-week range.
• Beta of 2.49 and position vs 200-day MA +68% — the tape is extreme above trend; the community's 'buyout rumors incoming' framing captures the M&A optionality building in the story.

July 30 Q2 earnings plus the Q4 NDA full submission timeline is the confirming trajectory: positive Phase 3 data plus specific regulatory milestone commentary is what keeps the run alive; a delayed NDA submission or a durability concern in the data is where the +274% T12M gain gives back. Real psychedelic-approval frontrunner with real Phase 3 data — the setup rewards continued regulatory disclosure and is asymmetric event-heavy.